- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S8846
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| MDA-MB-468 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth after 72 hrs by MTT assay, GI50=0.046μM | 26023867 | ||
| MDA-MB-231 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT assay, GI50=0.073μM | 26023867 | ||
| HEK293T | Function assay | Inhibition of CREB-mediated gene transcription in human HEK293T cells transfected with pCRE-RLuc by renilla luciferase reporter assay, IC50=0.081μM | 26023867 | |||
| HEK293T | Function assay | 30 mins | Inhibition of CREB (unknown origin) expressed in HEK293T cells assessed as inhibition of forskolin-induced CREB transcription activity incubated for 30 mins by luciferase reporter gene assay, IC50=0.081μM | 31765143 | ||
| MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth after 72 hrs by MTT assay, GI50=0.31μM | 26023867 | ||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay, GI50=0.47μM | 26023867 | ||
| HEK293T | Function assay | 30 mins | Inhibition of NFkappaB (unknown origin)-mediated gene transcription in human HEK293T cells transfected with an NFkappaB firefly luciferase reporter gene assessed as inhibition of TNFalpha-stimulated gene transcription pretreated for 30 mins measured after, IC50=5.29μM | 26023867 | ||
| HEK293T | Function assay | 50 nM | 1 hr | Inhibition of CREB-mediated gene transcription in human HEK293T cells assessed as inhibition of forskolin-stimulated Nurr1/NR4A2 transcription at 50 nM after 1 hr by qRT-PCT analysis | 26023867 | |
| HEK293T | Function assay | > 1 uM | 30 mins | Inhibition of VP16/CREB (unknown origin) interaction in human HEK293T cells assessed as inhibition of forskolin-stimulated gene transcription at > 1 uM after 30 mins by CRE-RLuc complementation assay | 26023867 | |
| HEK293T | Function assay | > 1 uM | 30 mins | Inhibition of P53 (unknown origin) transfected in human HEK293T cells assessed as inhibition of forskolin-stimulated gene transcription at > 1 uM after 30 mins by CRE-RLuc complementation assay | 26023867 | |
| MDA-MB-468 | Antitumor assay | 10 mg/kg | 5 weeks | Antitumor activity against human MDA-MB-468 cells xenografted in BALB/c mouse assessed as reduction in tumor volume at 10 mg/kg, ip once a day, 5 days per week for 5 weeks relative to control | 26023867 | |
| HEK293T | Function assay | 100 nM | 1 hr | Inhibition of CREB in HEK293T cells assessed as inhibition of Fsk-induced NR4A2 gene expression at 100 nM pre-incubated for 1 hr before Fsk stimulation for 45 mins by qRT-PCR analysis | 31765143 | |
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 100 mg/mL
(161.15 mM)
Ethanol : 3 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 620.52 | Formula | C33H31Cl2N3O5 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1433286-70-4 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1=CC=C2C=C(C(=CC2=C1)C(=O)NCCOC3=CC4=CC=CC=C4C=C3C(=O)NC5=C(C=C(C=C5)Cl)O)OCCCN.Cl | ||
| Targets/IC50/Ki |
CREB
81 nM
|
|---|---|
| In vitro |
Compound 3i (666-15) could potently inhibit cancer cell growth. In MDA-MB-231 and MDA-MB-468 cells, the GI50 for this compound is 73 and 46 nM, respectively. In A549 and MCF-7 cells, it exhibits robust activity as well with GI50 of 0.47 and 0.31 μM. It inhibits CREB’s transcription activity in living cells independent of direct CREB or CBP binding interaction. |
| In vivo |
In an in vivo MDA-MB-468 xenograft model, compound 3i (666-15) completely suppresses tumor growth without overt toxicity. Preliminary toxicity studies show that intraperitoneal (ip) injection of 10 mg/kg of it is well tolerated in mice. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.